Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Clovis Oncology Inc (CLVS)

Clovis Oncology Inc (CLVS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Help
Go To:
Author
Analysts Holding As Pfizer Waits On Two Phase 3 Studies MarketBeat - Fri Feb 24, 2023

Pfizer has two products with great potential, waiting on phase-3 study results. The resulting revenue increase should also improve share value.

PFE : 24.94 (-0.64%)
MDVN : 81.48 (+0.05%)
AZN : 63.20 (-0.94%)
CLVS : 0.0812 (-5.58%)
TSRO : 74.96 (+0.03%)
BHVN : 46.83 (+1.14%)
Clovis Oncology Files for Chapter 11 Protection and Enters into Agreement to Sell FAP-2286 Business Wire - Sun Dec 11, 2022

Clovis Oncology, Inc. (NASDAQ:CLVS) (“Clovis” or the Company”), a biopharmaceutical company focused on acquiring, developing, and commercializing innovative anti-cancer agents in the U.S., Europe,...

CLVS : 0.0812 (-5.58%)
Wall Street - shutterstock_1321462400
Pre-Market Brief: Stocks Mixed As Labor Market Strength Weigh On Sentiment Barchart - Mon Dec 5, 2022

December S&P 500 futures (ESZ22) are trending down -0.30% this morning after three major US benchmark indices closed mixed on Friday as the November payrolls report fueled expectations the Federal Reserve...

ESZ22 : 3,871.47s (-0.66%)
TXMD : 1.3400 (+3.08%)
IOVA : 8.14 (-0.61%)
IMPP : 3.45 (-0.29%)
CLVS : 0.0812 (-5.58%)
UTHR : 364.33 (+1.00%)
SBUX : 98.26 (-0.09%)
Clovis: Q3 Earnings Snapshot AP - Wed Nov 9, 2022

Clovis: Q3 Earnings Snapshot

CLVS : 0.0812 (-5.58%)
Rising Incidence of Pancreatic Cancer Driving Demand for Advanced Treatment Therapies FinancialNewsMedia - Mon Nov 7, 2022

Palm Beach, FL – November 7, 2022 – FinancialNewsMedia.com News Commentary – While there is no cure for pancreatic cancer in the pancreatic cancer treatment market, new treatment options abound,...

ONCY : 0.9985 (-5.80%)
ONC.TO : 1.40 (-5.41%)
CLVS : 0.0812 (-5.58%)
OPK : 1.5800 (-2.47%)
CRDF : 2.53 (-3.44%)
MRK : 97.44 (+0.93%)
Clovis Oncology Highlights Updated LuMIERE Phase 1 Data of Targeted Radiotherapy Candidate FAP-2286 at the 35th Annual EANM Congress Business Wire - Mon Oct 17, 2022

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced an oral presentation at the 35 th Annual European Association of Nuclear Medicine Congress (EANM) detailing updated Phase 1 data from the Clovis Oncology-sponsored...

CLVS : 0.0812 (-5.58%)
TRITON3 Phase 3 Trial of Rubraca® (rucaparib) Achieves Primary Endpoint in Men with Metastatic Castration-Resistant Prostate Cancer with BRCA or ATM Mutations Business Wire - Mon Oct 3, 2022

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced positive top-line data from the Phase 3, open-label, multicenter, randomized TRITON3 trial demonstrating that Rubraca monotherapy treatment achieved...

CLVS : 0.0812 (-5.58%)
Clovis Oncology and Isotopia Announce Lutetium-177 Clinical Supply Agreement Business Wire - Wed Sep 21, 2022

Clovis Oncology, Inc. (NASDAQ: CLVS) and Isotopia Molecular Imaging Ltd. today announced the signing of a clinical supply agreement that provides Clovis Oncology with Isotopia’s lutetium-177 ( 177 Lu)...

CLVS : 0.0812 (-5.58%)
Why Clovis Oncology Zoomed 30% Higher Today Motley Fool - Mon Sep 12, 2022

The biotech delivers some highly encouraging news on the clinical front.

CLVS : 0.0812 (-5.58%)
BMY : 57.88 (-0.60%)

Barchart Exclusives

Stocks Slip Before the Open on Nvidia’s Disappointing Forecast and Ukraine Jitters, U.S. Economic Data on Tap Barchart - 48 minutes ago
December S&P 500 E-Mini futures (ESZ24) are down -0.31%, and December Nasdaq 100 E-Mini futures (NQZ24) are down -0.43% this morning as a disappointing revenue forecast from Nvidia and concerns about escalating Russia-Ukraine tensions dampened sentiment. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot